|
|
|
|
| Symbol |
private |
| Founded |
0 |
| Employees |
|
|
|
|
|
|
|
|
 |
| Summary Description |
| Diagnostic tests for early cancer detection |
|
| Management |
| Stan Yakatan, Chairman; Steve Sommer, MD, PhD, CEO; Juliana Barba, PhD, CSO |
| |
|
|
| |
|
|
|
|
|
|
|
|
| Description |
|
OncoMOTOR is a new company focused on developing highly sensitive diagnostic tests that can be used in either the doctorâ??s office or hospital to enable the very early diagnosis of cancer. The Company has harnessed the ability to track the effects of therapeutic drugs on cancer patients, and utilizes NextGen sequencing to identify a "signature" of three somatic mutations within a cancer. Pyrophosphorolysis Activated Polymerization (PAP) can often detect mutations at one part in a million or better; a personalized PAP assay can be developed to detect the cancer signature in plasma, the cellular component of blood, or another accessible tissue, and often does so at 0.5 centimeters or lower, which is below the detection of virtually all imaging methods. In those patients without a known cancer, a PAP assay can be used yearly to screen for about 7,000 mutations, which should provide a signature for 90% of all cancers in the body. The combination of PAP, NextGen sequencing, and interpretation make for a powerful combination for this earlier-stage biotechnology company. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members